1. 324 BDB001, a Toll-Like receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously and shows clinical responses in advanced solid tumors. (9th November 2020) Authors: Patel, Manish; Rasco, Drew; Johnson, Melissa; Tolcher, Anthony; Li, Lixin; Zong, Adam; Chung, Alexander; Andtbacka, Robert Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗